Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Select Advanced Solid Tumors 1Pain 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Humoral Hypercalcemia Of Malignancy 1Glioma 1Colorectal Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 22Paclitaxel 17Capecitabine 16fludarabine 15Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × Antibodies, Monoclonal × Clear all
NCT00060138 2013-05-15

Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

Chugai Pharmaceutical

Phase 1/2 Completed
Breast

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡